A 4-Week Dose-Ranging Study to Evaluate Antidyslipidemic Effects, Other Pharmacodynamic Effects, Safety, and Tolerability of AZD6610 with Concomitant Open-Label Simvastatin Therapy in Patients with Elevated Triglycerides, Elevated Low Density Lipid Cholesterol and Abdominal Obesity: a Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study with Fenofibrate as Reference

Study identifier:D4350C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 4-Week Dose-Ranging Study to Evaluate Antidyslipidemic Effects, Other Pharmacodynamic Effects, Safety, and Tolerability of AZD6610 with Concomitant Open-Label Simvastatin Therapy in Patients with Elevated Triglycerides, Elevated Low Density Lipid Cholesterol and Abdominal Obesity: a Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study with Fenofibrate as Reference

Medical condition

hypercholesterolaemia

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Sept 2006
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria